Role of protein tyrosine kinase inhibitors in cancer therapeutics

Indian Journal of Biochemistry and Biophysics

Volumn 41, Issue 6, 2004, Pages 273-280

  Bhise, S B ^a   Nalawade, Abhijit D ^a   Wadhawa, Hitesh ^a  

^a Govt College of Pharmacy   (India)

Author keywords

Acute myeloid leukemia; Anticancer agent; Chronic myeloid leukemia; Epidermal growth factor receptor; Gastrointestinal stromal tumor; Imatinib mesylate; Protein tyrosine kinase; Tyrosine kinase inhibitors; Vascular endothelial growth factor

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 4 (3 CHLORO 4 FLUOROANILINO) 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; 5 (5 FLUORO 1,2 DIHYDRO 2 OXO 3 INDOLYLIDENEMETHYL) 2,4 DIMETHYL 1H PYRROLE 3 CARBOXYLIC ACID (2 DIETHYLAMINOETHYL)AMIDE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 7 HYDROXYSTAUROSPORINE; AG 013726; BIRB 0796; BRYOSTATIN 1; CEP 1347; CEP 701; CHIR 200131; ERLOTINIB; EVEROLIMUS; FLAVOPIRIDOL; GEFITINIB; GENE EXPRESSION MODULATOR 231; IMATINIB; INDISULAM; ISIS 3521; KRN 633; LAPATINIB; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 (1 METHYL 4 PIPERIDINYLMETHOXY) 4 QUINAZOLINAMINE; N [4 (3 CHLORO 4 FLUOROANILINO) 7 (3 MORPHOLINOPROPOXY) 6 QUINAZOLINYL]ACRYLAMIDE; N BENZOYLSTAUROSPORINE; PKC 312; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN 2,2 BIS(HYDROXYMETHYL)PROPIONATE; ROSCOVITINE; RUBOXISTAURIN; SCIO 469; SEMAXANIB; SORAFENIB; UNINDEXED DRUG; VATALANIB;

ANEMIA; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER THERAPY; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOPENIA; DIARRHEA; DRUG POTENCY; ENZYME INHIBITION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LIVER TOXICITY; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; RASH; SHORT SURVEY; SIDE EFFECT; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; HUMANS; MODELS, CHEMICAL; MODELS, MOLECULAR; NEOPLASMS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECURRENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 15744388104     PISSN: 03011208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (71)

1. Traxler P (1998) Tyrosine kinase inhibitors in cancer treatment. Expert Opin Ther Pat 8, 1599-1625
2. Pawson T & Nash P (2000) Protein-protein interactions define specificity in signal transduction. Genes Dev 14, 1027-1047
3. Schlessinger J (2000) Cell signalling by receptor tyrosine kinases. Cell 103, 211-225
4. Hanahan D & Weinberg R A (2000) The hallmark of cancer. Cell 100, 57-70
5. Hunter T (2000) Signaling-2000 and beyond. Cell 100, 113-127
6. Blume-Jensen P & Hunter T (2001) Oncogenic kinase signalling. Nature (London) 411, 355-365
7. Medema R H & Bos J L (1993) The role of p21ras in receptor tyrosine kinase signaling. Crit Rev Oncog 4, 615-661
8. Smithgall T E (1995) SH2 and SH3 domains: potential targets for anti-cancer drug design. J Pharmacol Toxicol Methods 34, 125-132
9. Neet K & Hunter T (1996) Vertebrate non-receptor protein-tyrosine kinase families. Genes Cells 1, 147-169
10. Ogawa A, Takayama Y, Sakai H, Chong K T, Takeuchi S, Nakagawa A, Nada S, Okada M & Tsukihara T (2002) Structure of the Carboxyl-terminal Src Kinase, Csk. J Biol Chem 277, 14351-14354
11. Nada S, Shima T, Yanai H, Husi H, Grant S G N, Okada M & Akiyama T (2003) Identification of PSD-93 as a substrate for the Src-family tyrosine kinase Fyn. J Biol Chem (USA) 278, 47610-47621
12. Lu Y, Yu Q, Liu J H, Zhang J, Wang H , Koul D, McMurray J S, Fang X, Yung W K A, Siminovitch K A & Mills G B (2003) Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-Kinase/AKT cascades. J Biol Chem 278, 40057-40066
13. Lee S, Lin X, Nam N, Parang K & Sun G (2003) Determination of the substrate-docking site of protein tyrosine kinase C-terminal Src kinase. Proc Natl Acad Sci (USA) 100, 14707-14712
14. Lin X, Lee S & Sun G (2003) Functions of the activation loop in Csk protein-tyrosine kinase. J Biol Chem 278, 24077
15. Yaish P, Gazit A & Gilon C (1988) Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 242, 933-935
16. McMahon G, Sun L, Liang C & Tang C (1998) Protein kinase inhibitors: Structural determinants for target specificity. Curr Opin Drug Discov Dev 1, 131-146
17. Klein J M, DeWild L J & McCarthy T A (1998) Effect of tyrosine kinase inhibition on surfactant protein A gene expression during human lung development. Am J Physiol 274, 542-551
18. Grunwald V & Hidalgo M (2003) Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 95, 851-867
19. Walking A E (2002) Epidermal growth factor receptor tyrosine kinase inhibitors. Curr Opin in Phamacol 2, 382-387
20. Traxler P, Bold G, Buchdanger E, Caravatti G, Furet P, Manley P O, O'Reilly T, Wood J & Zimmermann J (2001) Tyrosine kinase inhibitors: -from rational design to clinical trials. Med Res Rev 21, 499-512
21. Voldberg B R, Spang-Thomsen M & Palsen H S (1997) Epidermal growth factor receptor and EGF-R mutations, function and possible role in clinical trials. Ann Oncol 8, 1197-1206
22. Moulder S L, Yakes F M, Muthuswamy S K, Bianco R, Simpson J F & Arteaga C L (2001) Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-over-expressing breast cancer cells in vitro and in vivo. Cancer Res 61, 8887-8895
23. Chan K C, Knox W F, Gee J M, Morris J, Nicholson R I, Potten C S & Bundred N J (2002) Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer Res 62, 122-128
24. Sirotnak F M, Zakowski M F, Miller V A, Scher H I & Kris M G (2000) Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6, 4885-4892
25. Bono J S & Rowinsky E K (2002) The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med (Suppl.) 8, 19-26
26. Baselga J (2002) Why the epidermal growth factor receptor? The rationale for cancer therapy. The Oncologist (Suppl.) 7, 2-8
27. Ferrara N & Gerber H P (2002) The role of VEGF in angiogenesis. Acta Haematol 106, 148-156
28. Oosthuyse B, Moons L, Strokebaum E, Beck H, Nuyens D, Brusselmans K, Van Dorpe J, Helling P, Gorselink M Heymans S, Theilmeier G, Dewerchin M, Laudenbach V, Vermylen P, Raat H, Acker T, Vleminckx V, Van Den Bosch L, Cashman N, Fujisawa H, Drost M R, Sciot R, Bruyninckx F, Hicklin D J, Ince C, Gressens P, Lupu F, Plate K H, Robberecht W, Herbert J M, Collen D & Carmeliet P (2001) Deletion of the hypoxia response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Grenet 28, 131-138
29. Shakespeare W C (2001) SH2 domain inhibition: a problem solved? Curr Opin Chem Biol 5, 409-415
30. Ferrara N (1993) Vascular endothelial growth factor. Trends Cardiovasc Med 3, 244-250
31. Schoenberger J, Grimm D, Kossmehl P, Infanger M, Kurth E & Eillies C (2004) Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of poorly differentiated thyroid carcinoma: an animal study. Endocrinology 145, 1031-1038
32. Breier G & Risau W (1996) The role of VEGF in blood vessel formation. TIBC 6, 454-456
33. Koelch W, Martiny-Baron G, Kieser A & Marme D (1995) Regulation of the expression of VEGF/VPS and it's receptors. Role in tumor angiogenesis. Breast Cancer Res Treat 36, 139-155
34. Wood J M, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rosel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch K H, Schneider M R, Drevs J, Martiny-Baron G, Totzke F & Marme D (2000) PTK787/ZK222584, a novel and potent inhibitor of vascular endothelial growth factor induced responses and tumor after oral administration. Cancer Res 60, 2178-2189
35. Yano S, Herbst R S, Shinohara H, Knighton B, Bucana C D, Killion J J, Wood J & Fidler I J (2000) Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res 6, 955-965
36. Xu L, Yoneda J, Herrera C, Wood J, Killion J J & Fidler I J (2000) Inhibition of malignant ascites and growth of ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol 16, 445-454
37. th ASCO Annual Meeting; New Orleans, LA. June 5-8, 2004 Abstract No. 1512
38. Baker C H, Solorzano C C & Fidler I J (2002) Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res 62, 1996-2003
39. Kuenen B C, Levi M, Meijers J C M, Van Hinsbergh V W M, Berkhof J, Kakkar A K, Hoekman K & Pinedo H M (2003) Potential role of platelets in endothelial damage observed during treatment with Cisplatin, Gemcitabine, and the angiogenesis inhibitor SU5416. J Clin Oncol 21, 2192-2198
40. Itokawa T, Nokihara H, Nishioka Y, Sone S, Iwamoto Y, Yamada Y, Cherrington J, McMahon G, Shibuya M, Kuwano M & Ono M (2002) Antiangiogenic effect by SU5416 is partly attributable to inhibition of Fit-1 receptor signaling. Mol Cancer Ther 1, 295-302
41. Zangari M, Anaissie E, Stopeck A, Morimoto A, Tan N, Lancet J, Cooper M, Hannah A, Garcia-Manero G, Faderl S, Kantarjian H, Cherrington J, Albitar M & Giles F J (2004) Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res 1, 88-95
42. Kuenen B C, Tabernero J, Baselga J, Cavalli F, Pfanner E, Conte P F, Seeber S, Madhusudan S, Deplanque G, Huisman H, Scigalla P, Hoekman K & Harris A L (2003) Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res 9, 1648-1655
43. Goldman J M & Melo J V (2001) Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344, 1084-1086
44. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R & Kantarjian H M (1999) The biology of chronic myeloid leukemia. N Engl J Med 341, 164-172
45. Druker B J, Talpaz M, Resta D J, Peng B, Buchdunger E, Ford J M, Lydon N B, Kantarjian H, Capdeville R, OhnoJones S & Sawyers C L (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344, 1031-1037
46. Sawyers C L (1999) Medical Progress: Chronic myeloid leukaemia. N Engl J Med 340, 1330-1340
47. Goldman J (1997) ABC of clinical haematology: Chronic myeloid leukemia. Br Med J 314, 657-664
48. Cohen M H, Williams G, Johnson J R, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim S K, Wood R, Rothmann M, Chen G, U Khin M, Staten A M & Pazdur R (2002) Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8, 935-942
49. Goldman J M & Druker B J (2001) Chronic myeloid leukemia: Current treatment options. Blood 98, 2039-2042
50. Kantarjian H M, Sawyers C, Hochhaus A, Guilhot F, Schifer C, Gambacorti-Passerini C, Niederweiser D, Resta D, Capdeville R, Zoellner U, Talpaz M & Druker B (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346, 645-652
51. Kantarjian H M, Talpaz M, O'Brien S, Giles F, Gracia-Manero G, Fadrel S, Thomas D, Shan J, Rios M B & Cortes J (2003) Dose escalation of imatinib mesylate can overcome resistance to standard dose therapy in patients with chronic myelogenous leukemia. Blood 101, 473-475
52. May Thomas S (2003) Gleevec: Tailoring to fit. Drug Disc Today 8, 188-189
53. Fabbro D, Parkinson D & Matter A (2002) Protein tyrosine kinase inhibitors: new treatment modalities? Curr Opin in Pharmacol 2, 374-381
54. Druker B J, Tamura S, Buchdunger E, Ohno S, Segal G M, Fanning S, Zimmermann J & Lydon B (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med 2, 561-566
55. Druker B J, Sawyers C L, Kantarjian H, Resta D J, Reese S F, Ford J M, Cadeville R & Talpez M (2001) Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with Philadelphia chromosome. N Engl Med 344, 1038-1042
56. Gracia-Manero G & Kantarjian H M (2002) Treatment innovations in chronic myelogenous leukemia. Oncology Special Edition 5, 139-143
57. Van Oosterom A T, Judson T, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S & Nielsen O S (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358, 1421-1423
58. th Annual Meeting; May 12-15, 2001; San Francisco, CA. Abstract No. 2. Available at: http://www.asco.org
59. Cerrantes F, Hernandez-Boluda J C, Steegmann J L, Conde E, Alvarez-Larran A, Lopez-Jimenez J, Osorio S, Villalon L, Camos M, Gracia-Conde J & Odriozola J (2003) Imatinib mesylate therapy of chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients. Haematologica 88, 1117-1122
60. Cortes J, Giles F, O'Brien S, Thomas D, Garcia-Manero G, Rios M B, Faderl S, Verstovsek S, Ferrajoli A, Freireich E J, Talpaz M & Kantarjian H (2003) Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-α. Blood 102, 83-86
61. Novartis Package literature for Gleevec. East Hanover, N J (2002): Novartis Pharmacteuticals Corporation; 2002. Available at: http://www.pharma.us. novartis.com/product/pi/pdf/Gleevec.pdf
62. Nardi V, Azam M & Daley G (2004) Mechanisms and implications of imatinib resistance mutations in Bcr-Abl. Curr Opin in Hematol 11, 35-43
63. Roskoski R (2003) STI-571: an anticancer protein-tyrosine kinase inhibitor. Biochem and Biophy Res Comm 309, 709-717
64. Hochhaus A, Kreil S, Corbin A S, La Rosee P, Muller M C, Lahaye T, Hanfstein B, Schoch C, Cross N C, Berger U, Gschaidmeier H, Druker B J & Hehlmann R (2002) Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16, 2190-2196
65. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Kerry T, Herrmann R, Lynch K P & Hughes T P (2002) High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99, 3472-3475
66. Roche-Lestienne C, Soenen-Cornu V, Grardel -Duflos N, Lai J L, Philippe N, Facon T, Fenaux P & Preudhomme C (2002) Several types of mutations of the AbI gene can be found in chronic myeloid leukemia patients resistant to STI 571, and they can pre- exist to the onset of treatment. Blood 100, 1014-1018
67. Roumiantsev S, Shah N P, Gorre M E, Nicoll J, Brasher B B, Swayers C L & Van Etten R A (2002) Clinical resistance to the kinase inhibitor STI571 in chronic myeloid leukemia by mutation of Tyr-252 in the Abl kinase domain P-loop. Proc Natl Acad Sci (USA) 99, 10700-10705
68. Shah N P, Nicoll J, Nagar B, Gorre M E, Paquette R L, Kuriyan J & Swayers C L (2002) Multiple BCR-ABL Kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117-125
69. Talpaz M, Silver R T, Druker B J, Goldman J M, Gambacorti-Passerini C, Guilhot F, Schiffer C A, Fischer T, Deininger M W, Lennard A L, Hochhaus A, Ottmann O G, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon F X, Fernandes-Reese S, Gathmann I, Capdeville R, Kantarjian H M & Sawyers C L (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99, 1928-1937
70. Product Information: Gleevec™, imatinib mesylate. Novartis Pharmaceuticals Canada Inc., Dorval, Quebec (PI issued 09/2001) reviewed 10/2001
71. Mauro M J & Druker B J (2001) STI571: Targeting Bcr-Abl as therapy for CML (2001) The Oncologist 6, 233-238